PharmaNutra S.p.A. (BIT:PHN), an Italian company specialising in mineral-based nutritional supplements and medical devices for muscles and joints, announced on Wednesday that it has signed an agreement with a strategy consulting company to define the development plan for its US subsidiary.
PharmaNutra USA Corp, based in Florida, distributes and markets PharmaNutra's products in the United States.
Following a recent market analysis, the US consulting firm will work over two months to draft a growth plan in partnership with PharmaNutra. The aim is to enhance business development in the US market, where PharmaNutra has received numerous patents and scientific recognitions from the medical community in recent years.
Roberto Lacorte, PharmaNutra S.p.A. CEO, said: "The design of this plan marks a significant advancement for PharmaNutra USA's business, a project we strongly support. We are pleased to partner with a leading consulting firm that has confirmed the growth drivers identified by PharmaNutra S.p.A. and the substantial potential of the American market for our product range."
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation
PharmaNutra signs agreement with strategic consulting firm for US development plan
BD launches advanced Intraosseous Vascular Access System for rapid emergency use
Pulsenmore to supply 25,000 home ultrasound devices to Clalit Health Services
Medtronic announces new, long-term data from SPYRAL HTN-ON MED clinical trial
Senzime unveils next-gen TetraGraph TOF monitor at ANESTHESIOLOGY 2024; US shipments to begin in Q4
Abbott launches new clinical trial to improve results in patients with advanced heart failure
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Adocia patents stable hormone combinations for obesity and diabetes